Tim Wehner1, Shahidul Mannan2, Sanchit Turaga3, Kirtana Vallabhaneni4, Hao Meng Yip5, Carys Wiggans6, Rohit Shankar7, John S Duncan8, Josemir W Sander9. 1. NIHR UCL Hospitals Biomedical Research Centre, UCL Institute of Neurology, Queen Square WC1N 3BG, and Chalfont Centre for Epilepsy, Chalfont St Peter SL9 0RJ, UK. Electronic address: tim.wehner@gmail.com. 2. NIHR UCL Hospitals Biomedical Research Centre, UCL Institute of Neurology, Queen Square WC1N 3BG, and Chalfont Centre for Epilepsy, Chalfont St Peter SL9 0RJ, UK. Electronic address: shahidul.mannan@uclh.nhs.uk. 3. NIHR UCL Hospitals Biomedical Research Centre, UCL Institute of Neurology, Queen Square WC1N 3BG, and Chalfont Centre for Epilepsy, Chalfont St Peter SL9 0RJ, UK. Electronic address: Sanchit.turaga.11@ucl.ac.uk. 4. NIHR UCL Hospitals Biomedical Research Centre, UCL Institute of Neurology, Queen Square WC1N 3BG, and Chalfont Centre for Epilepsy, Chalfont St Peter SL9 0RJ, UK. Electronic address: kirtana.vallabhaneni.12@ucl.ac.uk. 5. NIHR UCL Hospitals Biomedical Research Centre, UCL Institute of Neurology, Queen Square WC1N 3BG, and Chalfont Centre for Epilepsy, Chalfont St Peter SL9 0RJ, UK. Electronic address: hao.yip.12@ucl.ac.uk. 6. Cornwall Partnership NHS Foundation Trust, Adult Developmental Neuropsychiatry, Chygovenck, Threemilestone Industrial Estate, Threemilestone, Truro TR4 9LD, UK. Electronic address: carys.wiggans@nhs.net. 7. Cornwall Partnership NHS Foundation Trust, Adult Developmental Neuropsychiatry, Chygovenck, Threemilestone Industrial Estate, Threemilestone, Truro TR4 9LD, UK. Electronic address: Rohit.shankar@nhs.net. 8. NIHR UCL Hospitals Biomedical Research Centre, UCL Institute of Neurology, Queen Square WC1N 3BG, and Chalfont Centre for Epilepsy, Chalfont St Peter SL9 0RJ, UK. Electronic address: j.duncan@ucl.ac.uk. 9. NIHR UCL Hospitals Biomedical Research Centre, UCL Institute of Neurology, Queen Square WC1N 3BG, and Chalfont Centre for Epilepsy, Chalfont St Peter SL9 0RJ, UK; Stichting Epilepsie Instellingen Nederland (SEIN), Achterweg 5, Heemstede 2103SW, The Netherlands. Electronic address: l.sander@ucl.ac.uk.
Abstract
RATIONALE: Observational data on antiepileptic drugs (AEDs) inform about their use in clinical practice. We describe our clinical experience with perampanel (PER) in a large UK tertiary epilepsy center. METHODS: Adults initiated on PER between October 2012 and March 2015 were followed until they discontinued PER or 10 September 2016. Data on epilepsy syndrome, duration, seizure types, concomitant and previous AED use, PER dosing, efficacy and side effects were recorded. Efficacy was categorized as temporary or ongoing (at last follow-up) seizure freedom, ≥50% seizure reduction, or other benefit (e.g. No convulsions or daytime seizures). These categories were mutually exclusive except for people with temporary seizure freedom. RESULTS: 391 received a PER prescription, five of whom never took it. No follow-up data were available for ten. 83% had focal epilepsy. People were prescribed PER in addition to 1-7 (Interquartile range [IQR] 2, 2, 3) AEDs and had previously used up to 18 (IQR 5, 7, 10) AEDs. Total exposure was 639patient/years. Retention rates were 60.4% at one year, 48.3% at two years, and 42.7% at three years. 19 (5%) people reported seizure free periods lasting at least six months. A ≥50% reduction in seizures lasting at least six months was reported by 76 people (20%), and marked improvement for ≥6months was seen in 52 (14%). Five (1%) were taken off other AEDs and continued on PER monotherapy for 4-27months. Seizures were aggravated in 57 (15%). Somatic side effects were reported by 197 (52%), mostly CNS. Mood changes, irritability or challenging behavior were reported by 137 (36%). PER was discontinued by 211 (56%) due to adverse effects (39%), inefficacy (26%), or both (35%). No idiosyncratic adverse events were seen. CONCLUSION: PER resulted in some benefit in 40% of those exposed. Adverse effects on mental health and on balance were common and should be discussed with people before initiating PER.
RATIONALE: Observational data on antiepileptic drugs (AEDs) inform about their use in clinical practice. We describe our clinical experience with perampanel (PER) in a large UK tertiary epilepsy center. METHODS: Adults initiated on PER between October 2012 and March 2015 were followed until they discontinued PER or 10 September 2016. Data on epilepsy syndrome, duration, seizure types, concomitant and previous AED use, PER dosing, efficacy and side effects were recorded. Efficacy was categorized as temporary or ongoing (at last follow-up) seizure freedom, ≥50% seizure reduction, or other benefit (e.g. No convulsions or daytime seizures). These categories were mutually exclusive except for people with temporary seizure freedom. RESULTS: 391 received a PER prescription, five of whom never took it. No follow-up data were available for ten. 83% had focal epilepsy. People were prescribed PER in addition to 1-7 (Interquartile range [IQR] 2, 2, 3) AEDs and had previously used up to 18 (IQR 5, 7, 10) AEDs. Total exposure was 639patient/years. Retention rates were 60.4% at one year, 48.3% at two years, and 42.7% at three years. 19 (5%) people reported seizure free periods lasting at least six months. A ≥50% reduction in seizures lasting at least six months was reported by 76 people (20%), and marked improvement for ≥6months was seen in 52 (14%). Five (1%) were taken off other AEDs and continued on PER monotherapy for 4-27months. Seizures were aggravated in 57 (15%). Somatic side effects were reported by 197 (52%), mostly CNS. Mood changes, irritability or challenging behavior were reported by 137 (36%). PER was discontinued by 211 (56%) due to adverse effects (39%), inefficacy (26%), or both (35%). No idiosyncratic adverse events were seen. CONCLUSION: PER resulted in some benefit in 40% of those exposed. Adverse effects on mental health and on balance were common and should be discussed with people before initiating PER.
Authors: Josemir W Sander; William E Rosenfeld; Jonathan J Halford; Bernhard J Steinhoff; Victor Biton; Manuel Toledo Journal: Epilepsia Date: 2021-11-23 Impact factor: 6.740
Authors: Jacqueline A French; Steve S Chung; Gregory L Krauss; Sang Kun Lee; Maciej Maciejowski; William E Rosenfeld; Michael R Sperling; Marc Kamin Journal: Epilepsia Date: 2021-07-13 Impact factor: 5.864